Bioengineering Human Tissue With Humacyte's Dr. Heather Prichard
Humacyte COO Dr. Heather Prichard joins the Business of Biotech for a discussion on the company's pipeline of candidates for the repair, replacement, and reconstruction of human vascular vessels. The company recently scaled the production of its implantable bioengineered human tissues from 10 to 200 per day to meet Phase 3 vascular trauma and arteriovenous access trials. On today's episode, Dr. Prichard shares the company's scale-up story and the science and engineering behind a unique approach to regenerative medicine using human tissue.
LISTEN TO THE PODCAST! Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X
Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.
Subscribe to Biosimilar Development X
Subscribe to Biosimilar Development